Glaucoma		Bimatoprost
OAG		Lumigan

Pictures

9976bio1 jpg

Optical Coherence Tomography from Bioptigen Gets Award Optical coherence tomography OCT a technology often described as combining the principles of ultrasound with the imaging performance of a microscope is thought to be particularly useful

---

eye camera1 h jpg

New Light Sensor Mimicks Eye for Superior Camera Performance One of the disadvantages of modern photo cameras is the flat image sensor that converts light into electric signals Because of its shape optics must make up for various aberrations that

---

eye camera2 photo jpg

location affixed to a glass lens Over the last 20 years many researchers have tried to manufacture such electronic eye systems but until now none were able to create a working camera This strategy opens up exciting new engineering design possibilities by eliminating the two dimensional planar constraints of conventional semiconductor wafer based optoelectronics said

---

xChart31 jpg

patients were so relieved that their glaucoma was controlled that they weren t concerned about the color of their irides On the other hand hyperemia is reversible and corrects itself CONFIRMING EARLIER STUDIES Based on findings from our study we concluded that bimatoprost is a more efficacious drug across the board compared with latanoprost Smaller studies suggested this

---

45858re jpg

TONO PEN AVIA Tonometer Gets MDEA Award Tono Pen Avia applanation tonometer a device designed to diagnose glaucoma and other intraocular pressure disorders is another winner of this year s Medical Design Excellence Awards

---

secondsight prost jpg

Second Sight Medical Retinal Prosthesis to Receive a Wider Trial LiveMint Wall Street Journal s Indian business website is reporting that California s Doheny Eye Institute is teaming up with a hospital in Bangalore to conduct the second phase of trial

---

xChart13 jpg

term direct comparisons have suggested that bimatoprost packs a greater punch we needed a long term study to determine which was ultimately most effective Here s a summary of what we found THE STUDY Our large controlled study of 269 patients in 18 centers in the United States was designed to determine how much IOP decreased during treatment with bimatoprost 0 03 and

---

screw under scope jpg

as well as anterior diseases such as glaucoma The I vation™ Sustained Drug Delivery System has now entered Phase IIb of clinical trial in patients with diabetic macular edema From the device brochure SurModics has developed the I vation Sustained Drug Delivery System for the sustained release of drugs to the back of the eye The I vation platform offers a great

---

523epiret1 jpg

Epi Ret Retinal Implant At Aachen University Clinic and the Fraunhofer Institute for Microelectronic Circuits in Germany scientists are developing an epiretinal implant for people suffering from retinitis pigmentosa

---

xChart17 jpg

Produced higher responder rates Here are the highlights of our study ► When we analyzed the mean change from baseline IOP which was the primary endpoint our data consistently showed that bimatoprost outperformed

---

3463lpr2 jpg

formulation of the therapeutic protein Ciliary Neurotrophic Factor CNTF designed to be released into the vitreous body from a proprietary Encapsulated Cell Technology ECT device More about Neurotech s technology platform and the NT 501 Neurotech s core technology platform is Encapsulated Cell Technology ECT a unique technology that allows for the long term

---

Lumigan gif

---

65234ss1 jpg

Argus II Retinal Prosthesis Implanted Into First Two Patients in Europe Times Online is reporting that Alfred Mann s 2nd Sight Medical has enrolled two patients from the UK into a clinical trial of the company s 60 electrode array Argus II Retinal Prosthesis

---

Picture25 gif

15 and 20 reductions in IOP Significantly Greater Mean IOP Reductions With Bimatoprost at All Time Points Bimatoprost Superior to Latanoprost in Primary Endpoint

---

Picture13 gif

No Change in Mean IOP at 8 AM After Switching to Bimatoprost Monotherapy Equivalent Clinical Success With Bimatoprost Monotherapy and Timolol Latanoprost

---

Figure 18 jpg

for ophthalmic use was latanoprost 0 005 solution Xalatan® This drug was followed by travoprost 0 004 solution Travatan® and bimatoprost 0 03 solution Lumigan® Figure 18 Ophthalmic prostaglandins for glaucoma treatment From left to right latanoprost 0 005 Xalatan® travoprost 0 004 Travatan® and bimatoprost 0 03 Lumigan® Images

---

xSlide2 jpg

compared bimatoprost and latanoprost for diurnal control The results of this study which are presented below showed that bimatoprost outperformed latanoprost at every time point DETERMINING TARGET PRESSURES Our primary goal when treating glaucoma patients should be to lower IOP aggressively always considering risk factors such as age and health status as well as

---

Picture14 gif

Equivalent Clinical Success With Bimatoprost Monotherapy and Timolol Latanoprost Summary

---

thera2 jpg

reduction in IOP with bimatoprost Two of the 15 patients experienced an IOP reduction of less than 20 with bimatoprost and one had a reduction of less than 10 Figure 2 |Figure 2 This graph shows the mean diurnal IOP at baseline and at the end of each treatment phase in the study eye s Data adapted from Gandolfi SA Cimino L Effect of

---

01 lumigan shadow jpg

Bimatoprost Lumigan Allergan is the third member of this elite drug class Because of its somewhat unique chemical structure it has to be more concentrated i e

---